Article Text

Download PDFPDF
Women’s health and midwifery
Intimate partner violence educational programmes may improve healthcare professionals’ knowledge of and readiness to respond to women’s experiences of violence
  1. Rebecca J. Seymour1,
  2. Susan M. Jack2
  1. 1 Centre for Intelligent Healthcare, Coventry University, Coventry, West Midlands, UK
  2. 2 School of Nursing, McMaster University, Hamilton, Ontario, Canada
  1. Correspondence to Dr Rebecca J. Seymour, Coventry University, Coventry CV1 5FB, UK; rebeccajseymour{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: Kalra N, Hooker L, Reisenhofer S, et al. Training healthcare providers to respond to intimate partner violence against women. Cochrane Database Syst Rev 2021;5:CD012423. doi: 10.1002/14651858.CD012423.PUB2

Implications for practice and research

  • Intimate partner violence (IPV) education programmes for healthcare providers should be regular and augmented by the implementation of system (or institution)-wide resources, pathways and policies to support individuals in successfully addressing women’s experiences of violence.

  • Future evaluations of training programmes should include assessments that measure actual (not just perceived) behavioural outcomes in practice and examine the relationship between providers’ educational outcomes and women’s safety and well-being.


Global estimates indicate that approximately one in three women has experienced physical and/or sexual IPV, or non-partner violence, across their lifespan.1 Experiences of IPV have significant short-term and long-term impacts on women’s physical, mental, sexual and reproductive health, and their children’s well-being. Healthcare providers (HCPs) are well positioned to identify and respond to IPV. The World Health Organization’s (WHO)2 clinical and policy guidelines for health sectors’ response to IPV strongly …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.